Cindy Medina Pabon, MD, discusses the clinical relevance of the FDA approval of zolbetuximab for CLDN18.2-positive gastric or GEJ adenocarcinoma.
Cindy Medina Pabon, MD
Advertisement
Articles by Cindy Medina Pabon, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS
4
Subgroup Analyses Confirm Clinically Meaningful Revumenib Responses in AML Across Mutational Profiles
5